Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities
Open Access
- 12 August 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (8), e23085
- https://doi.org/10.1371/journal.pone.0023085
Abstract
We estimated the effectiveness of four monovalent pandemic influenza A (H1N1) vaccines (three unadjuvanted inactivated, one live attenuated) available in the U.S. during the pandemic. Patients with acute respiratory illness presenting to inpatient and outpatient facilities affiliated with four collaborating institutions were prospectively recruited, consented, and tested for influenza. Analyses were restricted to October 2009 through April 2010, when pandemic vaccine was available. Patients testing positive for pandemic influenza by real-time RT-PCR were cases; those testing negative were controls. Vaccine effectiveness was estimated in logistic regression models adjusted for study community, patient age, timing of illness, insurance status, enrollment site, and presence of high-risk medical conditions. Pandemic virus was detected in 1,011 (15%) of 6,757 enrolled patients. Fifteen (1%) of 1,011 influenza positive cases and 1,042 (18%) of 5,746 test-negative controls had record-verified pandemic vaccination >14 days prior to illness onset. Adjusted effectiveness (95% confidence interval) for pandemic vaccines combined was 56% (23%, 75%). Adjusted effectiveness for inactivated vaccines alone (79% of total) was 62% (25%, 81%) overall and 32% (−92%, 76%), 89% (15%, 99%), and −6% (−231%, 66%) in those aged 0.5 to 9, 10 to 49, and 50+ years, respectively. Effectiveness for the live attenuated vaccine in those aged 2 to 49 years was only demonstrated if vaccination >7 rather than >14 days prior to illness onset was considered (61%∶ 12%, 82%). Inactivated non-adjuvanted pandemic vaccines offered significant protection against confirmed pandemic influenza-associated medical care visits in young adults.Keywords
This publication has 30 references indexed in Scilit:
- Safety and Effectiveness of a 2009 H1N1 Vaccine in BeijingNew England Journal of Medicine, 2011
- Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control StudyPLoS Medicine, 2011
- Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in EnglandThe Journal of Infectious Diseases, 2011
- Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 monthsVaccine, 2010
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Estimating influenza vaccine effectiveness using routinely collected laboratory dataJournal of Epidemiology and Community Health, 2009
- Comparative Efficacy of Inactivated and Live Attenuated Influenza VaccinesNew England Journal of Medicine, 2009
- Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 SeasonThe Journal of Infectious Diseases, 2009
- Prevention of Symptomatic Seasonal Influenza in 2005–2006 by Inactivated and Live Attenuated VaccinesThe Journal of Infectious Diseases, 2008
- Prevention of Antigenically Drifted Influenza by Inactivated and Live Attenuated VaccinesNew England Journal of Medicine, 2006